je.st
news
Tag: drugs
ASCO 2015: MATCHing, - linquing' just-right drugs to patients as research TAPURs to precision
2015-06-02 13:05:19| Logistics - Topix.net
Vowing to make precision medicine more than a hackneyed phrase, researchers at the American Society of Clinical Oncology annual meeting disclosed the launch of three separate but complementary efforts in what amounts to the "expansion of an ongoing dream," said past ASCO president Clifford Hudis. A medical oncologist at Memorial Sloan Kettering Cancer Center in New York, Hudis said medicine needs to find new ways of evaluating drugs according to the molecular characteristics of tumors.
Tags: to
research
patients
drugs
Tests for new cancer drugs not reliable enough, doctors say
2015-06-02 08:56:21| Biotech - Topix.net
CHICAGO: Drugmakers including Bristol-Myers Squibb Co and Merck & Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Bristol's Opdivo and Merck's Keytruda are both therapies designed to block a protein known as Programmed Death receptor that tumors use to evade the body's natural defenses.
Tags: say
tests
cancer
reliable
ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO
2015-06-02 03:40:01| Biotech - Topix.net
The biggest upside surprise from the American Society for Clinical Oncology meeting in Chicago, which ends Tuesday, probably came from , a beleaguered biotech that came back to life thanks to its antibody drug conjugate mirvetuximab soravtansine, or IMGN853. The drug's objective response rate - the percentage of tumors that shrank - was 53%, which induced several price-target increases and an upgrade to equal weight from Morgan Stanley.
Tags: drugs
scrutiny
surprises
asco
Lean years behind it, Eli Lilly sees growth in new drugs
2015-05-31 15:39:30| Food - Topix.net
Lean years behind it, Eli Lilly sees growth in new drugs "We had to find our true grit," CEO John Lechleiter says of past five years Check out this story on IndyStar.com: http://indy.st/1HDLXCO The loss of 60 percent of its revenue from patent expirations from 2011-2014 put Eli Lilly and Co. at risk.
Lean years behind it, Eli Lilly sees growth in new drugs
2015-05-31 14:26:47| Agriculture - Topix.net
Lean years behind it, Eli Lilly sees growth in new drugs "We had to find our true grit," CEO John Lechleiter says of past five years Check out this story on IndyStar.com: http://indy.st/1HDLXCO The loss of 60 percent of its revenue from patent expirations from 2011-2014 put Eli Lilly and Co. at risk.
Sites : [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] next »